Research Article

Screening of Cognitive Impairment in Patients with Multiple Sclerosis: A Cross-Sectional Study in Georgia

Table 5

Characteristics of MS patients with and without DMT.

MS patients on DMTMS patients without DMT

Number of subjects, n (%)27 (40%)41 (60%)
Age (years), mean ± SD37.6 ± 9.240.3 ± 10.4
Female, n (%)18 (66.7%)30 (73%)
Male, n (%)9 (33.3%)11 (27%)
Education < 15 years19 (70%)20 (49%)
Education ≥15 years8 (30%)21 (51%)
Unemployed12 (44%)20 (49%)
Employed25 (55%)35 (59%)

MS subtype
RRMS23 (85%)29 (70.7%)
SPMS4 (15%)8 (19.5%)
PPMS4 (9.8%)

Disease duration (years), mean ± SD6.7 ± 4.67.1 ± 6.5
EDSS (years), mean ± SD2.6 ± 1.33.7 ± 1.7
BDI ≥ 193 (11%)11 (27%)
CI11 (41%)21 (51%)

BDI: Beck Depression Inventory; CI: cognitive impairment; DMT: disease-modifying therapy; EDSS: Expanded Disability Status Scale; PPMS: primary progressive multiple sclerosis; RRMS: relapsing-remitting multiple sclerosis; SD: standard deviation; SPMS: secondary progressive multiple sclerosis.